ANGELA V DAVIS
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care GOODYEAR, AZ NPI 1992296768
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care AZ Acerta Pharma LLC All categories
General Payments — all program years on this page
$587.96
- Category: General Payments
- Program years: PY2021–2024
- Record count: 16
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $292.17 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $292.17 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $150.43 | 2 |
| Merck Sharp & Dohme Corporation | $56.87 | 3 |
| Genentech USA, Inc. | $31.24 | 1 |
| Genmab U.S., Inc. | $30.49 | 1 |
| Novo Nordisk AS | $23.14 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1100358268 | Novo Nordisk Inc | $23.14 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105699466 | AstraZeneca Pharmaceuticals LP | $28.60 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105863062 | AstraZeneca Pharmaceuticals LP | $121.83 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1126834090 | Genmab U.S., Inc. | $30.49 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1133142582 | Genentech USA, Inc. | $31.24 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1141627537 | Merck Sharp & Dohme LLC | $21.92 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1141627539 | Merck Sharp & Dohme LLC | $16.02 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1141919012 | Merck Sharp & Dohme LLC | $18.93 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.